Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

Rethinking Molecular Profiling after First-line Osimertinib

Summary

A recent study from the ORCHARD program provided the largest histogenomic characterization of first-line osimertinib resistance mechanisms. Utilizing dual-modality sequencing on both tissue and plasma samples, resistance alterations were identified in 87% of patients. Furthermore, polyclonal mechanisms were detected in 46% of patients, highlighting the intricate biological landscape post-osimertinib treatment. These findings prompt a re-evaluation of post-EGFR tyrosine kinase inhibitor therapeutic strategies, weighing targeted versus broadly acting regimens.

Critical appraisal

Clinical. This study, while not providing direct efficacy data, highlights the intricate nature of first-line osimertinib resistance, a standard treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The detection of resistance alterations in a large majority of patients (87%) and the prevalence of polyclonal mechanisms (46%) suggest that a single targeted therapy post-osimertinib might be insufficient. This justifies clinical trials evaluating combination therapies or broader approaches after osimertinib failure. The clinical impact is medium-term (3-5 years) for integrating these data into second-line treatment strategies.

Molecular biology. The key discovery is the in-depth histogenomic characterization of osimertinib resistance mechanisms, showing a high detection rate of alterations and a significant proportion of polyclonality. The technology employed, dual-modality sequencing (tissue and plasma), is critical as it allows for a more comprehensive detection of resistance mechanisms, including those potentially missed by a single modality or emerging in liquid biopsies. The ability to detect polyclonal mechanisms underscores the need for exhaustive molecular testing after progression on osimertinib. These findings validate the importance of post-treatment molecular profiling and could lead to the development of more sophisticated clinical tests to guide subsequent therapies.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology